Piper Sandler downgraded Collegium Pharmaceutical to Neutral from Overweight with an unchanged price target of $39. With the stock up 64% over the past 12 months, the shares are essentially reflecting the cumulative cash generation from the Nucynta franchise, Xtampza ER and Belbuca, the analyst tells investors in a research note. The firm cites valuation for the downgrade.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COLL:
- Collegium Pharmaceutical authorizes generic agreement with Hikma
- Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
- Collegium Pharmaceutical announces redemption of convertible senior notes
- Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026